CliffBio
small molecule

XELJANZ XR

TOFACITINIB CITRATE

Loss of exclusivitySeptember 2034latest FDA-listed patent expiry
CompanyPfizer →See this company's full patent-cliff portfolio

Drug detail

Brand nameXELJANZ XR
Active ingredientTOFACITINIB CITRATE
StrengthEQ 22MG BASE
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2019
Marketing statusRX

Listed patents

PatentExpiresType
10639309*PEDSeptember 2034—
11253523*PEDSeptember 2034—
11253523March 2034use U-3329
10639309March 2034product
RE41783*PEDJune 2026—
RE41783December 2025substance

More from Pfizer

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

XELJANZ XR patent cliff — loss of exclusivity September 2034 | CliffBio